Skip to Content

Carboplatin is a Viable Option in Treating Patients with Completely Resected Non-Small Cell Lung Cancer

A new study suggests that carboplatin offers a higher tolerability measured by discontinuation rates than cisplatin, and that there was no significant difference in recurrence rates. In this MEDtalk, Vivi Quoc Nguyen from Odense University Hospital presents the results of this study that compared patients who had received cisplatin and vinorelbine to those who had received carboplatin and vinorelbine.

Vivi Quoc Nguyen

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top